Digi International Bolsters Digi Connect EZ Family of Device Servers with Launch of 8/16/32 Port Options
6.4.2023 15:00:00 EEST | Business Wire | Press release
Digi International, (NASDAQ: DGII, www.digi.com), a leading global provider of Internet of Things (IoT) connectivity products and services, today announced the launch of Digi Connect® EZ 8/16/32. This solution represents the latest in Digi’s line of next-generation device servers providing secure, scalable connectivity for business, commercial, and industrial automation applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230406005005/en/
Digi Connect EZ 8/16/32 comes with a one-year subscription to Digi’s LifeCycle Assurance Program, providing customers with access to Digi Remote Manager Premier edition and 24/7 expert technical support. (Photo: Business Wire)
The product expansion underscores Digi’s commitment to supporting critical industries spanning utilities, energy, aerospace, government, commercial, logistics and factory automation with intelligent end-to-end serial connectivity solutions. Combining state-of-the-art hardware with the robust Digi Accelerated Linux (DAL) operating system, the Digi Connect EZ 8/16/32 line offers a range of industry-leading features. These include cellular support and the unparalleled central management capabilities of Digi Remote Manager® (Digi RM). This platform enables in-depth, 360-degree visibility to configure, deploy, and manage remote assets securely.
Also included with Digi Connect EZ 8/16/32 is a one-year subscription to Digi’s LifeCycle Assurance Program, providing customers with access to Digi Remote Manager Premier edition and 24/7 expert technical support.
“We are excited to expand the Digi Connect EZ family, providing enhanced solutions and devices that enable our customers to conveniently and securely scale their operations today, while preemptively addressing the IIoT challenges of tomorrow,” said Brian Kirkendall, General Manager and Vice President of Infrastructure Management at Digi. “The incorporation and availability of our wider product features such as cellular support, central management with Digi RM, and round-the-clock expert assistance underscore Digi’s ongoing commitment to supporting customers throughout the entire product lifecycle.”
Hardware-enabled and software-defined, the Connect EZ family of products delivers a scalable solution that supports multiple serial interfaces in both industrial and non-industrial environments. Digi Connect EZ prevents data loss, providing state of the art communication technology to meet the needs of machine-to-machine serial communication customers all over the world. Additionally, the Connect EZ family offers an updated hardware platform that ensures longevity, manageability, and deployment flexibility. To manage critical serially connected equipment at scale, the Connect EZ family adheres to the following key attributes:
- Scalability — Simple click-to-connect deployment using Digi Navigator, with quick configuration providing easy integration for a wide range of use cases. Digi Connect EZ is truly easy to deploy and manage at scale throughout the product lifecycle with robust security, management and device health capabilities.
- Reliability — Built on top of the Digi TrustFence® design architecture and DAL operating system, Digi Connect EZ is designed for deployment in industrial environments to offer a secure, stable, and resilient platform for mission-critical connectivity, including LTE and Wi-Fi.
- Capability — Supports a wide range of industry standard and device-specific protocols using serial tunneling, and TCP/UDP connections or Digi’s patented RealPort® COM port redirector for remote native COM port access. Additionally, the built-in Python environment enables application development and customization at the device level, including event-based programmability, data conversion and full control of device connections.
“No matter the industry, no matter the challenge — from industrial automation to large scale manufacturing to secure communication of critical data — we’ve got our customers covered,” Kirkendall continued. “With the Connect EZ 8/16/32 expansion, we’re delivering the scalable and secure end-to-end connectivity solution our customers not only need, but that they deserve.”
Availability
Digi Connect EZ® 8/16/32 devices are available for immediate purchase now.
Explore the solutions here:
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services and solutions. We help our customers create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, we’ve helped our customers connect over 100 million things and growing. For more information, visit Digi's website at www.digi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005005/en/
Contact information
Peter Ramsay
Global Results Communications
digi@globalresultspr.com
949.307.5908
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom